

MAKING RELIABLE TESTS
A REALITY FOR ALL TO

END TUBERCULOSIS



Every year, almost half of people with tuberculosis (TB) are not diagnosed or notified to health systems – resulting in **millions of preventable deaths**.

IN 2021

10.6 million
people

FELL ILL WITH TB¹

~40% of
cases

REMAINED UNDIAGNOSED¹

Nearly
450,000
people

DEVELOPED
MULTIDRUG-RESISTANT
TB (MDR-TB)¹

Only
1 in 3
people

RECEIVED THE
APPROPRIATE TEST
AND TREATMENT
FOR MDR-TB¹

UNDIAGNOSED
AND UNTREATED,
A PERSON WITH
ACTIVE TB CAN
TRANSMIT THE
INFECTION TO

10-15
people a year²

To reduce TB deaths by 90% by 2030, we need **simple, rapid tests that work for everyone, everywhere.**

FIND IS WORKING WITH PARTNERS TO



ENABLE UNIVERSAL ACCESS TO TB DIAGNOSTICS

with tools that work in community and primary healthcare settings and use samples that are easy and convenient for all people to provide.

- Multi-pathogen point-of-care molecular tests
- Swab and urine-based testing
- Person-centred delivery models
- Integrated testing



PRESERVE DRUGS & TREATMENT REGIMENS

by testing response to critical drugs, directing patients to effective treatments, and safeguarding against antimicrobial resistance.

- New drug-resistance tests
- Next-generation sequencing (NGS)
- Capacity building and infrastructure upgrades
- Diagnostic network optimization (DNO)



INTERRUPT DISEASE TRANSMISSION

and drive the development and uptake of tests and digital tools that promote community screening and early detection of TB in all its forms.

- Imaging and computer-assisted detection (CAD)
- Simpler tools for TB infection
- AI and digital diagnostic support
- Active case-finding strategies

STRENGTHEN TB TESTING AT EVERY LEVEL OF THE HEALTHCARE SYSTEM

HOME



HEALTH CENTRE



HOSPITAL

1. WHO. Global Tuberculosis Report, 2022. Available at: <https://www.who.int/publications/i/item/9789240061729>

2. WHO. Tuberculosis Q&A. January 2018. Available at: <https://www.who.int/news-room/questions-and-answers/item/tuberculosis>

ENSURING EVERYONE WHO NEEDS A TB TEST CAN GET ONE

Taking advantage of new and existing technologies, FIND is working to develop solutions that increase the availability of diagnostic tools for TB and improve access to them. Our focus is on meeting the needs of key groups and populations (such as children and people living with HIV), and the expansion of diagnostic testing to make it available everywhere that people seek care.

OUR IMPACT IN NUMBERS (2010–2022)

27 new diagnostic tools

17 countries

WITH OPTIMIZED TB DIAGNOSTIC NETWORKS

6 WHO recommendations supported

4.2M+ people tested

FOR TB & DRUG-RESISTANT TB AT FIND-SUPPORTED LABORATORIES IN INDIA

200,000 drug-resistant TB cases

NOTIFIED IN INDIA

SPOTLIGHTS

TB TESTS TO IMPROVE DIAGNOSIS IN CHILDREN

New molecular stool-based tests have the power to transform diagnostic testing for TB in children. With product development and evaluation supported by FIND, WHO formally recommended their use in 2021. Nine countries have since adopted stool-based testing, with FIND providing technical assistance to others looking to take advantage of this important new test. In India, molecular testing has been enabled for nearly 95,000 children with suspected TB between 2014 and 2018 with 89% of those diagnosed linked to treatment.

A JOINT EFFORT FOR THE ELIMINATION OF TB IN INDIA

Launched in 2018, this project is the largest private-sector health engagement initiative for TB ever to be carried out in India. As an implementing partner, FIND helped notify over 200,000 people with TB in 3 years and increase treatment adherence to over 80%. The second phase of work provides preventative TB treatment to household contacts of people with pulmonary TB in four Indian states. As of August 2023, over 300,000 contacts have been screened, with more than 200,000 people starting preventative treatment and more than 8 out of 10 people completing the course.

NEW TOOLS TO IMPROVE COMMUNITY-BASED TESTING

In a study of over 4,000 people, the TB-CAPT consortium demonstrated that placing battery-operated molecular diagnostic tests in primary healthcare centres in Tanzania and Mozambique improved case detection rates and demonstrated that a same-day test-and-treat strategy is feasible for TB. The approach was implemented in a low-resource setting and was shown to be feasible, practical and widely acceptable to patients and healthcare workers alike.


INFORMING POLICIES TO HARNESS NEW TECHNOLOGIES

Targeted next-generation sequencing (tNGS) can cut the detection and profiling of drug-resistant TB from months to days. Advances in artificial intelligence (AI) can expand TB screening services by supporting chest X-ray reading to address the global shortage of radiologists. As policy-makers welcome new technologies, FIND is on-track to become a certified WHO prequalification assessor, supporting with clinical validation, as well as roll-out and implementation of approved new tools.

“The 2030 goal of ending TB remains ambitious, but the roadmap to get there is clear and **diagnostic testing is a critical element** to stop transmission and save lives.”

MORTEN RUHWALD, DIRECTOR OF TB, FIND

WITH THANKS TO OUR KEY DONORS SUPPORTING OUR TB WORK



FIND OUT MORE